TrialAnnals of oncology : official journal of the European Society for Medical Oncology2017

SELECT-2: a phase II, double-blind, randomized, placebo-controlled study to assess the efficacy of selumetinib plus docetaxel as a second-line treatment of patients with advanced or metastatic non-small-cell lung cancer.

J-C Soria et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.